BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21345220)

  • 1. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus?
    von Rahden BH; Kircher S; Lazariotou M; Reiber C; Stuermer L; Otto C; Germer CT; Grimm M
    J Exp Clin Cancer Res; 2011 Feb; 30(1):23. PubMed ID: 21345220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.
    Becker L; Huang Q; Mashimo H
    Dis Esophagus; 2010 Feb; 23(2):168-74. PubMed ID: 19549212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status.
    Grimm M; Lazariotou M; Kircher S; Stuermer L; Reiber C; Höfelmayr A; Gattenlöhner S; Otto C; Germer CT; von Rahden BH
    J Transl Med; 2010 Oct; 8():99. PubMed ID: 20946664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.
    Vega KJ; May R; Sureban SM; Lightfoot SA; Qu D; Reed A; Weygant N; Ramanujam R; Souza R; Madhoun M; Whorton J; Anant S; Meltzer SJ; Houchen CW
    J Gastroenterol Hepatol; 2012 Apr; 27(4):773-80. PubMed ID: 21916995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
    Nancarrow DJ; Clouston AD; Smithers BM; Gotley DC; Drew PA; Watson DI; Tyagi S; Hayward NK; Whiteman DC; ;
    PLoS One; 2011; 6(7):e22513. PubMed ID: 21829465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.
    Jin Z; Wang L; Cao Z; Cheng Y; Gao Y; Feng X; Chen S; Yu H; Wu W; Zhao Z; Dong M; Zhang X; Liu J; Fan X; Mori Y; Meltzer SJ
    BMC Cancer; 2014 May; 14():345. PubMed ID: 24885118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.
    Jin Z; Wang L; Zhang Y; Cheng Y; Gao Y; Feng X; Dong M; Cao Z; Chen S; Yu H; Zhao Z; Zhang X; Liu J; Mori Y; Fan X; Meltzer SJ
    Sci Rep; 2013 Oct; 3():2838. PubMed ID: 24088706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and functional regulation of stemness gene Lgr5 in esophageal squamous cell carcinoma.
    Lv Z; Yu JJ; Zhang WJ; Xiong L; Wang F; Li LF; Zhou XL; Gao XY; Ding XF; Han L; Cai YF; Ma W; Wang LX
    Oncotarget; 2017 Apr; 8(16):26492-26504. PubMed ID: 28404917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia.
    Neyaz A; Odze RD; Rickelt S; Nieman LT; Bledsoe JR; Mahadevan KK; Arora K; Jeck WR; Taylor MS; Gala M; Patil DT; Yilmaz OH; Rivera MN; Ting DT; Deshpande V
    Clin Transl Gastroenterol; 2020 Dec; 12(1):e00272. PubMed ID: 33464729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
    Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
    Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
    Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
    World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
    Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
    Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic biomarkers in esophageal cancer.
    Kaz AM; Grady WM
    Cancer Lett; 2014 Jan; 342(2):193-9. PubMed ID: 22406828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
    Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
    Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.